Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Blood - Tập 110 Số 10 - Trang 3540-3546 - 2007
Hagop M. Kantarjian1, Francis J. Giles1, Norbert Gattermann2, Kapil N. Bhalla3, Giuliana Alimena4, Francesca Palandri5, Gert J. Ossenkoppele6, Franck-Emmanuel Nicolini7, Stephen J. O’Brien8, Mark R. Litzow9, Ravi Bhatia10, Francisco Cervantes11, Md Ariful Haque12, Yaping Shou12, Debra Resta12, Aaron Weitzman12, Andreas Hochhaus13, Philipp le Coutre14
1M.D. Anderson Cancer Center, Houston, TX
2Universitaetsklinikum Duesseldorf, Duesseldorf, Germany;
3H. Lee Moffitt Cancer Center, Tampa, FL
4Azienda Policlinico Umberto I-Universita La Sapienza, Rome, Italy;
5S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy
6Vrije University (VU) Medisch Centrum, Amsterdam, the Netherlands;
7Hópital Edouard Herriot, Lyon, France;
8Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
9Mayo Clinic College of Medicine, Rochester, MN;
10City of Hope National Medical Center, Duarte, CA
11Hospital Clinic, Barcelona, Spain
12Novartis Pharmaceuticals, Florham Park, NJ
13III Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany; and
14Campus Virchow Klinikum, Charité, Humboldt-Universität, Berlin, Germany

Tóm tắt

Abstract Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) after imatinib failure or intolerance. Patients had at least 6 months of follow-up and were evaluated for hematologic and cytogenetic responses, as well as for safety and overall survival. At 6 months, the rate of major cytogenetic response (Ph ≤ 35%) was 48%: complete (Ph = 0%) in 31%, and partial (Ph = 1%-35%) in 16%. The estimated survival at 12 months was 95%. Nilotinib was effective in patients harboring BCR-ABL mutations associated with imatinib resistance (except T315I), and also in patients with a resistance mechanism independent of BCR-ABL mutations. Adverse events were mostly mild to moderate, and there was minimal cross-intolerance with imatinib. Grades 3 to 4 neutropenia and thrombocytopenia were observed in 29% of patients; pleural or pericardial effusions were observed in 1% (none were severe). In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707.

Từ khóa


Tài liệu tham khảo

Faderl, 1999, The biology of chronic myeloid leukemia., N Engl J Med, 341, 164, 10.1056/NEJM199907153410306

Sawyers, 1999, Chronic myeloid leukemia., N Engl J Med, 340, 1330, 10.1056/NEJM199904293401706

O'Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia., N Engl J Med, 348, 994, 10.1056/NEJMoa022457

Kantarjian, 2004, High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia., Blood, 103, 2873, 10.1182/blood-2003-11-3800

Silver, 2004, Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract]., Blood, 104, 11a, 10.1182/blood.V104.11.23.23

Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia., N Engl J Med, 355, 2408, 10.1056/NEJMoa062867

Hochhaus, 2004, Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance., Leukemia, 18, 1321, 10.1038/sj.leu.2403426

Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification., Science, 293, 876, 10.1126/science.1062538

Shah, 2004, Overriding imatinib resistance with a novel ABL kinase inhibitor., Science, 305, 399, 10.1126/science.1099480

O'Hare, 2005, In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants., Cancer Res, 65, 4500, 10.1158/0008-5472.CAN-05-0259

Hochhaus, 2007, Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy., Blood, 109, 2303, 10.1182/blood-2006-09-047266

Talpaz, 2006, Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias., N Engl J Med, 354, 2531, 10.1056/NEJMoa055229

Weisberg, 2005, Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl., Cancer Cell, 7, 129, 10.1016/j.ccr.2005.01.007

Golemovic, 2005, AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukemia., Clin Cancer Res, 11, 4941, 10.1158/1078-0432.CCR-04-2601

Cowan-Jacob, 2007, Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia., Acta Crystallogr D Biol Crystallogr, 63, 80, 10.1107/S0907444906047287

Manley, 2006, Bcr-Abl binding modes of dasatinib, imatinib and nilotinib: an NMR study [abstract]., Blood, 108, 224a, 10.1182/blood.V108.11.747.747

Manley, 2007, Extended kinase profiling of the Bcr-Abl inhibitor nilotinib [abstract]., Proc Am Assoc Cancer Res, 48

Weisberg, 2006, AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL., Br J Cancer, 94, 1765, 10.1038/sj.bjc.6603170

Kantarjian, 2006, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL., N Engl J Med, 354, 2542, 10.1056/NEJMoa055104

Kantarjian, 1988, Characteristics of accelerated disease in chronic myelogenous leukemia., Cancer, 61, 1441, 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C

Kantarjian, 1987, Chronic myelogenous leukemia in blast crisis: an analysis of 242 patients., Am J Med, 83, 445, 10.1016/0002-9343(87)90754-6

Kantarjian, 2002, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia., N Engl J Med, 346, 645, 10.1056/NEJMoa011573

Quintas-Cardama, 2006, Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure [abstract]., Blood, 108

Thông tin
Thông tin xuất bản

Blood

Tập 110 Số 10

3540-3546

Thông tin tác giả